Is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for prostate and other cancers.

About us

CellCentric operates as a small core team working closely with a network of collaborators, consultants and contract research organisations (CROs) to deliver all aspects of drug target evaluation and validation, medicinal chemistry, translational research, pre-clinical and clinical development.

The company’s leadership has deep R&D experience gained in academia, large pharma and biotechs, spanning from basic biological research through to international clinical development programmes.

Our history

CellCentric originally span out of the University of Cambridge, drawing on the work of one of the pioneers of epigenetics, Prof Azim Surani FRS CBE.

Over time the company has investigated a wide range of epigenetic-related pathways to address disease. More than 50 potential drug targets have been investigated, before focussing on twin histone acteyltransferases p300/CBP. The selection was driven by strong biology, a clear path for developing selective and potent small molecule inhibitor drugs, as well as well-defined relevance and targeted application to treat cancer.

An early arginine methyltransferase programme was licenced to Takeda Pharmaceuticals.


We are developing CCS1477 for the large and growing population of prostate cancer patients that are unresponsive to second generation anti-hormonal drugs. The drug candidate also has potential for other oncology unmet needs, including for specific haematological, lung and bladder cancers. CCS1477 is a potent and highly selective small molecule drug that inhibits the conserved bromodomains of p300/CBP.

Clinical trials

CCS1477 is currently being trialled in patients with late stage, drug-resistant prostate cancer. A separate study is investigating its effects in patients with blood cancers (multiple myeloma, acute myeloid leukaemia, lymphomas).

Potential suitability for enrolment in a CCS1477 clinical trial will be made by oncologists at our participating hospitals, and not by CellCentric. Any advice on clinical study options should come from your general practitioner and/or oncologist.